

Amendment to HB 1022

1 Amend the title of the bill by replacing it with the following:

2

3 AN ACT permitting pharmacists to dispense the drug Ivermectin by means of a standing
4 order and establishing a commission to study the use of Ivermectin to treat Covid-19.

5

6 Amend RSA 318-47-n, I as inserted by section 1 of the bill by replacing it with the following:

7

8 I. In this section, "standing order" means a written and signed protocol authored by one or
9 more physicians licensed under RSA 329:12 or one or more advanced practice registered nurses
10 licensed under RSA 326-B:18. Such agreement shall specify a protocol allowing the pharmacist
11 licensed under RSA 318:18 to dispense Ivermectin under the delegated prescriptive authority of the
12 physician or advanced practice registered nurse, specify a screening protocol for each patient, specify
13 a requirement to document screening performed and the prescription in the patient's medical record,
14 and include a plan for referring for evaluation and treatment of adverse events; provided that the
15 standing order shall not be used if the patient is pregnant or under 18 years of age. Any such
16 prescription shall be regarded as being issued for a legitimate medical purpose in the usual course of
17 professional practice.

18

19 Amend the bill by replacing all after section 4 with the following:

20

21 5 New Subdivision; Commission to Study the Use of Ivermectin to Treat Covid-19 Established.

22 Amend RSA 126-A by inserting after section 97 the following new subdivision:

23

Commission to Study the Use of Ivermectin to Treat Covid-19

24 126-A:98 Commission to Study the Use of Ivermectin to Treat Covid-19. There is established a
25 commission to study use of Ivermectin to treat Covid-19.

26

I. The members of the commission shall be as follows:

27

28 (a) Three members of the house of representatives, appointed by the speaker of the
29 house of representatives, at least one of whom shall be a member of the house health, human
30 services and elderly affairs committee and one of whom shall be a member of the executive
31 departments and administration committee.

31

(b) One member of the senate, appointed by the president of the senate.

32

(c) The commissioner of the department of health and human services, or designee.

Amendment to HB 1022

- Page 2 -

1 (d) A representative of the New Hampshire board of pharmacy, appointed by the board.

2 (e) A representative of the board of nursing, appointed by the board.

3 (f) A representative of the board of medicine, appointed by the board.

4 (g) A representative of the New Hampshire Medical Society, appointed by the society.

5 (h) A representative of the New Hampshire Hospital Association, appointed by the
6 association.

7 (i) A representative of the New Hampshire Nurse Practitioners Association, appointed
8 by the association.

9 (j) A representative of the New Hampshire Pharmacist Association, appointed by the
10 association.

11 (k) Two members of the public, one of whom shall be appointed by the senate president
12 and one of whom shall be appointed by the speaker of the house of representatives.

13 II. Legislative members of the commission shall receive mileage at the legislative rate when
14 attending to the duties of the commission.

15 III. The commission shall examine national data on the use of Ivermectin to treat Covid-19,
16 relevant studies around the use of Ivermectin and work already being conducted by other states
17 standing orders. The commission shall review implementation of RSA 318:47-n, permitting
18 pharmacists to dispense Ivermectin by means of a standing order, and provide a recommendation as
19 to whether such authority should be made permanent.

20 IV. The members of the study commission shall elect a chairperson from among the
21 members. The first meeting of the commission shall be called by the senate member. The first
22 meeting of the commission shall be held within 45 days of the effective date of this section. A
23 majority of commission members shall constitute a quorum.

24 V. The commission shall report its findings and any recommendations for proposed
25 legislation to the president of the senate, the speaker of the house of representatives, the senate
26 clerk, the house clerk, the governor, and the state library on or before November 1, 2023.

27 6 Repeal. The following are repealed:

28 I. RSA 126-A:98 and the subdivision heading preceding RSA 126-A:98, relative to a
29 commission to study the use of Ivermectin to treat Covid-19.

30 II. RSA 318:47-n, authorizing pharmacists to dispense Ivermectin by means of a standing
31 order.

32 7 Effective Date.

33 I. Paragraph I of section 6 of this act shall take effect December 31, 2023.

34 II. Paragraph II of section 6 of this act shall take effect July 1, 2024.

35 III. Sections 1-4 of this act shall take effect 60 days after its passage.

36 IV. The remainder of this act shall take effect upon its passage.

Amendment to HB 1022
- Page 3 -

2022-1867s

AMENDED ANALYSIS

This bill allows pharmacists to dispense Ivermectin pursuant to a standing order. The authority is repealed July 1, 2024. The bill also establishes a commission to study the use of Ivermectin to treat Covid-19 and to provide a recommendation regarding whether to make the standing order permanent.